Dr. Sam Kulkarni
Showing 1–1 of 1 transcripts.
- Goldman Sachs29 min
Samarth Kulkarni, CEO, CRISPR Therapeutics
Samarth Kulkarni, Dr. Sam Kulkarni
Dr. Sam Kulkarni of CRISPR Therapeutics outlines a pivotal industry shift where the convergence of delivery systems and genome-editing technology enables a transition from chronic symptom management to one-time curative procedures for rare and common diseases. By leveraging a highly specific RNA passcode to mitigate off-target risks, the company is advancing both ex vivo and in vivo therapies, successfully treating blood disorders while expanding into metabolic conditions and sustainable agriculture. This strategic execution has allowed CRISPR Therapeutics to raise $3.5 billion and maintain an aggressive R&D focus despite a broader biotech market correction, positioning the firm to deliver the first wave of permanent genetic cures within the next decade.